Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Blood Cancer Journal
|
August 1, 2018
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
Miriam Marquis, Cyrielle Beaubois, Vincent-Philippe Lavallée, et al.
Blood Cancer Journal
|
March 2, 2019
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
Miriam Marquis, Cyrielle Beaubois, Vincent-Philippe Lavallée, et al.
The Journal of Cell Biology
|
September 16, 2015
Asymmetric cell division during T cell development controls downstream fate
Kim Pham, Raz Shimoni, Mirren Charnley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2020
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
Chong Chyn Chua, Andrew W Roberts, John Reynolds, et al.
Developmental Cell
|
July 21, 2010
Epidermal wound repair is regulated by the planar cell polarity signaling pathway
Jacinta Caddy, Tomasz Wilanowski, Charbel Darido, et al.
Nature Communications
|
September 1, 2018
Restricted cell cycle is essential for clonal evolution and therapeutic resistance of pre-leukemic stem cells
Cedric S Tremblay, Jesslyn Saw, Sung Kai Chiu, et al.
Best Practice & Research. Clinical Haematology
|
December 13, 2023
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry
Lucy C Fox, Zoe K McQuilten, Frank Firkin, et al.
Blood Cancer Journal
|
October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Advances
|
February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Advances
|
November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Blood Cancer Journal
|
August 1, 2018
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
Miriam Marquis, Cyrielle Beaubois, Vincent-Philippe Lavallée, et al.
Blood Cancer Journal
|
March 2, 2019
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
Miriam Marquis, Cyrielle Beaubois, Vincent-Philippe Lavallée, et al.
The Journal of Cell Biology
|
September 16, 2015
Asymmetric cell division during T cell development controls downstream fate
Kim Pham, Raz Shimoni, Mirren Charnley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2020
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
Chong Chyn Chua, Andrew W Roberts, John Reynolds, et al.
Developmental Cell
|
July 21, 2010
Epidermal wound repair is regulated by the planar cell polarity signaling pathway
Jacinta Caddy, Tomasz Wilanowski, Charbel Darido, et al.
Nature Communications
|
September 1, 2018
Restricted cell cycle is essential for clonal evolution and therapeutic resistance of pre-leukemic stem cells
Cedric S Tremblay, Jesslyn Saw, Sung Kai Chiu, et al.
Best Practice & Research. Clinical Haematology
|
December 13, 2023
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry
Lucy C Fox, Zoe K McQuilten, Frank Firkin, et al.
Blood Cancer Journal
|
October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Advances
|
February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Advances
|
November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Page
of 5